CA2517313A1 - Methodes et therapies de potentialisation des activites therapeutiques d'un agoniste de recepteurs cannabinoides par le biais de l'administration d'un antagoniste de recepteurs cannabinoides - Google Patents

Methodes et therapies de potentialisation des activites therapeutiques d'un agoniste de recepteurs cannabinoides par le biais de l'administration d'un antagoniste de recepteurs cannabinoides Download PDF

Info

Publication number
CA2517313A1
CA2517313A1 CA002517313A CA2517313A CA2517313A1 CA 2517313 A1 CA2517313 A1 CA 2517313A1 CA 002517313 A CA002517313 A CA 002517313A CA 2517313 A CA2517313 A CA 2517313A CA 2517313 A1 CA2517313 A1 CA 2517313A1
Authority
CA
Canada
Prior art keywords
cannabinoid receptor
receptor agonist
subject
pain
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002517313A
Other languages
English (en)
Inventor
Mary C. Olmstead
Jay J. Payquette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Queens University at Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University at Kingston filed Critical Queens University at Kingston
Priority to CA002517313A priority Critical patent/CA2517313A1/fr
Priority to US11/510,390 priority patent/US20070060638A1/en
Publication of CA2517313A1 publication Critical patent/CA2517313A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002517313A 2005-08-26 2005-08-26 Methodes et therapies de potentialisation des activites therapeutiques d'un agoniste de recepteurs cannabinoides par le biais de l'administration d'un antagoniste de recepteurs cannabinoides Abandoned CA2517313A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002517313A CA2517313A1 (fr) 2005-08-26 2005-08-26 Methodes et therapies de potentialisation des activites therapeutiques d'un agoniste de recepteurs cannabinoides par le biais de l'administration d'un antagoniste de recepteurs cannabinoides
US11/510,390 US20070060638A1 (en) 2005-08-26 2006-08-25 Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002517313A CA2517313A1 (fr) 2005-08-26 2005-08-26 Methodes et therapies de potentialisation des activites therapeutiques d'un agoniste de recepteurs cannabinoides par le biais de l'administration d'un antagoniste de recepteurs cannabinoides

Publications (1)

Publication Number Publication Date
CA2517313A1 true CA2517313A1 (fr) 2007-02-26

Family

ID=37806491

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002517313A Abandoned CA2517313A1 (fr) 2005-08-26 2005-08-26 Methodes et therapies de potentialisation des activites therapeutiques d'un agoniste de recepteurs cannabinoides par le biais de l'administration d'un antagoniste de recepteurs cannabinoides

Country Status (1)

Country Link
CA (1) CA2517313A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092267A1 (fr) * 2007-02-01 2008-08-07 Queen's University At Kingston Procedes et therapies pour potentialiser une action therapeutique d'un agoniste de recepteurs opioides et inhiber et/ou inverser une tolerance a des agonistes de recepteurs opioides
GB2491118A (en) * 2011-05-20 2012-11-28 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092267A1 (fr) * 2007-02-01 2008-08-07 Queen's University At Kingston Procedes et therapies pour potentialiser une action therapeutique d'un agoniste de recepteurs opioides et inhiber et/ou inverser une tolerance a des agonistes de recepteurs opioides
GB2491118A (en) * 2011-05-20 2012-11-28 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2524689A (en) * 2011-05-20 2015-09-30 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2491118B (en) * 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2524689B (en) * 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US9895342B2 (en) 2011-05-20 2018-02-20 Gw Pharma Limited Cannabinoids for use in the treatment of neuropathic pain

Similar Documents

Publication Publication Date Title
US20070060638A1 (en) Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
US11266612B2 (en) D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
CN1784221B (zh) 影响体重减轻的组合物
CN101080224B (zh) 治疗疼痛的组合物及其应用
US20230285329A1 (en) Methods and Compositions for the Treatment of Steatosis-Associated Disorders
US20100179129A1 (en) Compositions of an anticonvulsant and mirtazapine to prevent weight gain
Lacosta et al. MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine
WO2008009141A1 (fr) Procédés et thérapies permettant de potentialiser l'action thérapeutique d'un agoniste du récepteur adrénergique alpha-2 et inhiber et/ou inverser la tolérance aux agonistes du récepteur adrénergique alpha-2
WO2005107806A1 (fr) Compositions agissant sur une perte de poids
CZ299951B6 (cs) Kombinace úcinných látek pro medikamentózní terapii návykových nebo omamných prostredku
US20110053913A1 (en) Methods and Therapies for Alleviating Pain
US6780866B2 (en) Analgesic composition and method
Nayebi et al. Effect of chronic and acute administration of fluoxetine and its additive effect with morphine on the behavioural response in the formalin test in rats
CA2517313A1 (fr) Methodes et therapies de potentialisation des activites therapeutiques d'un agoniste de recepteurs cannabinoides par le biais de l'administration d'un antagoniste de recepteurs cannabinoides
WO2016005897A1 (fr) Association de prégabaline et de méloxicam pour le traitement de la douleur neuropathique
US20060069039A1 (en) Treatment of dyskinesia
JP2018515547A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
Singh et al. FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats
US20140094446A1 (en) Cyclic Amino Acids for the Treatment of Pain
EP3664787B1 (fr) Utilisation d'agonistes sélectifs du récepteur de la sérotonine 5-ht1a pour le traitement d'effets secondaires des inhibiteurs des vmat
KR101100002B1 (ko) 신경병증성 및 정신성 만성통증증후군의 치료 목적의약제의 제조를 위한 피리딘-2-일-메틸아민 유도체의 용도
US20080188508A1 (en) Methods and Therapies for Potentiating a Therapeutic Action of an Opioid Receptor Agonist and Inhibiting and/or Reversing Tolerance to Opioid Receptor Agonists
WO1998005207A1 (fr) Procede de traitement d'une agressivite excessive
Langman et al. Selective serotonin re-uptake inhibition attenuates evoked glutamate release in the dorsal horn of the anaesthetised rat in vivo
Touriño Raposo et al. MDMA attenuates THC withdrawal syndrome in mice

Legal Events

Date Code Title Description
FZDE Dead